GL9 Glanbia plc
Glanbia plc, together with its subsidiaries, operates as a nutrition company worldwide. The company offers sports nutrition and lifestyle nutrition products in various formats, such as powders, capsules, tablets, ready-to-eat bars, and ready-to-drink beverage. It also manufactures and sells cheese, dairy, and non-dairy nutritional and functional ingredients; and vitamin and mineral premixes products. In addition, the company engages in the financing business; property and land dealing business; property leasing; provision of business services and management solutions; and bioactive solutions. It offers its products under the Optimum Nutrition, BSN, Isopure, Nutramino, think!, Amazing Grass brands. The company sells its products through specialty retail, online, gym, and food, drug, mass, and club channels. Glanbia plc was founded in 1964 and is headquartered in Kilkenny, Ireland.…
Industry Peers
Packaged FoodsKey Statistics
About Glanbia (ISE: GL9)
›
Glanbia (ISE: GL9) is listed on Euronext Dublin, where its shares trade in EUR. It belongs to the Packaged Foods industry, part of the Consumer Defensive sector, and reports about 4,963 employees.
The shares were at 19.25 EUR on 20 November 2026, up 34.0% over 52 weeks. Its 52-week range is 14.09 EUR to 25.10 EUR: the price is 23.3% below the high and 36.6% above the low.
At a market capitalisation of 4.65B EUR, it trades at 23.2 times trailing earnings and 12.5 times forward earnings. The median trailing P/E of its 18 largest Packaged Foods peers is 24.8, so GL9 is valued in line with them. It pays a dividend yielding 2.23% (it pays out 51% of its earnings), against a median of 3.67% among the dividend payers in that peer group.
Glanbia reports return on equity of 9.5%, an operating margin of 9.6% and revenue up 7.9% year over year.
Its debt exceeds its cash by 832.20M USD, a debt-to-equity ratio of 0.58. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 10 analysts cover the stock, with an average rating of Buy; their mean price target of 24.07 EUR is 25.1% above the current price. The next earnings report is expected on 24 February 2027.